Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 16.04.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
16.04.23Affimed N.V.: Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meetin343AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent to Treat (ITT) populationPatients with Angioimmunoblastic...
► Artikel lesen
16.04.23Merck & Co., Inc. Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.360PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn's disease and other autoimmune conditions Prometheus Biosciences' comprehensive data set enables target discovery and precision...
► Artikel lesen
16.04.23Norsk Hydro: Strike at Hydro Karmøy and Hydro Årdal565Following the breach in mediation between The Confederation of Norwegian Enterprise (NHO), the Confederation of the Vocational Unions (YS) and the Norwegian Labor Union (LO), employees organized in...
► Artikel lesen
16.04.23F. Hoffmann-La Roche Ltd: Roche's Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study674In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1Up to 80% of people with this...
► Artikel lesen